BioAtla Inc. (NASDAQ: BCAB)
$1.92
+0.1700 ( +9.71% ) 555.4K
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
Market Data
Open
$1.92
Previous close
$1.75
Volume
555.4K
Market cap
$93.34M
Day range
$1.72 - $1.98
52 week range
$1.14 - $4.02
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 12 | Feb 12, 2024 |
4 | Insider transactions | 1 | Feb 01, 2024 |
4 | Insider transactions | 1 | Feb 01, 2024 |
4 | Insider transactions | 1 | Jan 19, 2024 |
8-k | 8K-related | 68 | Jan 09, 2024 |
8-k | 8K-related | 13 | Jan 08, 2024 |
4 | Insider transactions | 1 | Jan 03, 2024 |
4 | Insider transactions | 1 | Jan 03, 2024 |
4 | Insider transactions | 1 | Jan 03, 2024 |
4 | Insider transactions | 1 | Jan 03, 2024 |